Published in Cancer Weekly, April 27th, 1998
The development of safe vectors for gene therapy is an ever expanding field. An important area of vector design revolves around the development of a fail-safe mechanism that would allow clinicians to terminate therapy or remove the genetically altered cells at the end of treatment or in the case of deleterious effects.
Rebecca A. MacCorkle and colleagues from Baylor College of Medicine, Texas, used chemically induced dimerization to develop powerful death switches based on the cysteine proteases, caspase-1 ICE (interleukn-1(beta) converting enzyme) and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.